TOUCH

Please fill your contact details below:

BE IN

© 2019 by OPTCEUTICS.

Accelerating efficient drug development for retinal diseases 

 

ABOUT US

Optceutics Ltd. uses PK-Eye™, a dynamic ophthalmic pharmacokinetic model, to speed and enhance development of intravitreal injection and implant based biologic and pharmaceutical products.

 

PK-Eye can be used to:

  • Identify the right formulation technology

  • Optimise the selection of dose and dose frequency

  • Compare activity and duration to known products

  • Reduce program risk BEFORE moving into costly animal and human studies

  • Speed development of biosimilar products

  • Generate unique data to support additional patent coverage

 

Optceutics’ business model allows for fee for service research and strategic collaborations.

need for  

retinal therapy

Blinding diseases are an increasing burden to our ageing population. The recent introduction of intraocular biological based medicines such as antibodies has revolutionised the treatment of the wet form of age-related macular degeneration (AMD), which is the main cause of blindness in the elderly.  Biological therapies will continue to revolutionise retinal therapy.

Development of new therapies can be accelerated using the PK-Eye to augment traditional preclinical studies to minimise the risks of clinical studies. Optceutics provides rapid and cost-effective optimisation of retinal drugs and formulations.  The PK-Eye platform addresses many of the issues facing intraocular drug development by overcoming limitations of established preclinical models.

of ophthalmic therapies fail early stage clinical studies.

Developing long acting biological-based drugs designed for human use is not possible in animals because the animals quickly clear the drug by the formation of anti-drug antibodies (ADAs). Also, animal models do not mimic the ageing human vitreous, further limiting clinical translation.  

The pharmaceutical development of medicines (e.g. orally administered tablets and inhaled dry powder drugs) all rely on the extensive use of in vitro models to optimise performance.  Until the development of the PK-Eye, no model existed for the development of intraocular drugs.   

We have developed a two-compartment in vitro model of the human eye called the PK-Eye™ to accelerate the development of longer-acting intraocular medicines. The PK-Eye™ makes it more feasible to determine intraocular clearance times, dose escalation pharmacokinetic effects and stability profiles that are all needed for intraocular drug development. It significantly reduces and replaces animal use during preclinical development of ocular medicines. The PK-Eye™ enables more confident decision-making to increase the chances for the successful clinical translation of  intraocular therapies.

  

pk-

eye

see us next

CRS Annual Meeting and Exposition

21st July to 24th July in Valencia, Spain

ASRS Annual Meeting

26th July to 30th July in Chicago, US